Emerging analyses on retatrutide, a dual activator for GLP-1 and glucose-dependent insulinotropic polypeptide, demonstrate promising findings in managing obesity and type 2 glucose intolerance. Initial information from clinical experiments reveal substantial decreases in body weight and bettered